Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- Iqirvo (elafibranor)
- ritlecitinib
Interactions between your drugs
ritlecitinib elafibranor
Applies to: ritlecitinib, Iqirvo (elafibranor)
MONITOR: Coadministration with CYP450 3A4 inducers may decrease the plasma concentration and pharmacologic effects of ritlecitinib. The proposed mechanism is increased clearance of ritlecitinib due to induction of the CYP450 3A4 isoenzyme, one of the pathways of elimination of ritlecitinib. When a single 50 mg dose of ritlecitinib was administered in combination with the potent CYP450 3A4 inducer rifampin (600 mg once daily for 8 days), the mean peak plasma concentration (Cmax) and systemic exposure (AUC) of ritlecitinib decreased by approximately 25% and 44%, respectively, compared to ritlecitinib administered alone. Data are not available of other, less potent inducers.
MANAGEMENT: Caution is advised when ritlecitinib is used with CYP450 3A4 inducers. The possibility of diminished therapeutic effects should be considered.
References (1)
- (2023) "Product Information. Litfulo (ritlecitinib)." Pfizer U.S. Pharmaceuticals Group
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Ocaliva
Ocaliva may be used to treat primary biliary cholangitis (PBC) in adults without cirrhosis or with ...
Cosentyx
Cosentyx (secukinumab) is used to treat plaque psoriasis, psoriatic arthritis, ankylosing ...
Livdelzi
Livdelzi (seladelpar) is an oral prescription medicine that may be used to treat primary biliary ...
Actigall
Actigall is used for gallbladder disease, primary biliary cholangitis
Urso Forte
Urso Forte is used for gallbladder disease, primary biliary cholangitis
Reltone
Reltone is used for gallbladder disease, primary biliary cholangitis
Obeticholic acid
Obeticholic acid (brand name Ocaliva) may be used to treat primary biliary cholangitis (PBC) in ...
Ursodiol
Ursodiol information from Drugs.com, includes Ursodiol side effects, interactions and indications.
Seladelpar
Seladelpar is used to treat primary biliary cholangitis (PBC) in adults. It is a once-daily capsule ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.